恒瑞医药(600276.SH)药品纳入拟突破性治疗品种公示名单

Core Viewpoint - Heng Rui Medicine (600276.SH) announced that its subsidiaries, Suzhou Shengdiya Biopharmaceutical Co., Ltd. and Shanghai Shengdi Medicine Co., Ltd., have had their injectable drugs, SHR-A1811 and Adalimumab injection, included in the National Medical Products Administration's (NMPA) list of proposed breakthrough therapies, marking the ninth inclusion for SHR-A1811 [1] Group 1 - The injectable drug SHR-A1811 has been recognized for its potential as a breakthrough therapy, indicating significant progress in its development [1] - The inclusion in the proposed breakthrough therapy list is part of a public announcement period of 7 days, allowing for industry feedback and scrutiny [1] - This marks the ninth time SHR-A1811 has been included in the proposed breakthrough therapy list, highlighting its ongoing relevance and potential in the market [1]